Siliphos ® Clinical Studies Index
Read about studies conducted on Siliphos, the active ingredient in UltraThistle.
(Ref20C15) Effect of Siliphos® on chronic active hepatitis
Study shows significant reduction in elevated liver enzymes
(and therefore hepatocellular necrosis) in just one week of
treatment with Siliphos®.
(Ref21C13) Therapeutic effect of Siliphos® in chronic liver disease
A small study of eight human subjects with chronic active hepatitis.
This study shows significant benefits of Siliphos® after just
two months treatment.
(Ref8P22) Direct comparison of Siliphos® to standardized milk thistle extract
Study shows nearly 10x the bioavailability of Siliphos® over
the world's best selling standardized extract.
(Ref18C14) Useful dosages of Siliphos®:
Shows definite advantages of Siliphos® at dosages ranging from
160mg to 360mg (measured as silybin). Dose/effect relationship
is also demonstrated with the highest dosage tested getting
the most dramatic results.
(c10) Considerably greater bioavailability of silybin as a component
Laboratory study shows that binding silybin with phosphatidylcholine
on a molecular level dramatically improves its bioavailablity
on a cellular level.
(c3medline) Increased oral bioavailability
of Siliphos® in humans:
Human study compares Siliphos® and the worlds best selling standardized
milk thistle extract and shows how much better the results are
(Ref9C8) Effect of Siliphos® on cirrhotic
Study shows that Siliphos® does not significantly differ in
its safe and beneficial activity in patients with cirrhosis
vs. healthy control subjects.
(Ref10C2) Long term usage of Siliphos®:
Study shows the beneficial properties of Siliphos® are not diminished
by sustained usage of the product.
(Ref12P19) Liver damage control properties
Siliphos® shows significant protective activity against liver
damage. This study tested Siliphos® protection against a variety
(Ref13P6) Free radical scavenging properties of Siliphos®:
Study shows the capability of Siliphos® to scavenge free radicals
and inhibit lipid peroxidation. It also demonstrates significantly
higher blood plasma levels of silybin when administered as a
component of Siliphos® rather than in its unbound form.
(Ref14P13) Effect of silimarin on lipid peroxidation:
Study shows milk thistle extract (silymarin) to be a helpful
antioxidant and silybin to be the most valuable constituent
(Ref15P16) Siliphos® counteracts hepatotoxic
Study shows Siliphos® protects liver cells against free-radical
mediated toxic liver injury.
(Ref16P23) Antioxidant activity of
Siliphos® against alcohol:
Study shows how Siliphos® is dramatically more effective than
pure silybin alone. Concludes Siliphos® may be useful in counteracting
damage caused by alcohol intake.
(Ref19C6) Tolerablility and effectiveness of Siliphos®:
Study shows high dose tolerability of Siliphos® as well as its
increased effectiveness over conventional standardized milk
(c6medline) Liver protection potential
Study shows the antioxidant and free radical scavenging effect
(Ref7P12) Comparative bioavailability of Siliphos® vs. silybin:
Study shows exactly how much better silybin is absorbed when
combined on a molecular level with phosphatidylcholine (a patented
process resulting in Siliphos®).
(Ref11P1) Liver protective activity:
Shows Siliphos® is more effective than its constituents, silybin
and phosphatidylcholine, alone. The effectiveness of Siliphos®
is considerably greater than the sum of its parts.